Treatment of chronic lymphocytic leukemia: Achieving minimal residual disease - Negative status as a goal

Journal of Clinical Oncology

Volumn 23, Issue 13, 2005, Pages 2884-2885

  Montserrat, Emili ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; FLUDARABINE; MONOCLONAL ANTIBODY; PURINE DERIVATIVE; ANTINEOPLASTIC AGENT;

CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COMBINATION CHEMOTHERAPY; EDITORIAL; HUMAN; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; BIOASSAY; NOTE; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENDPOINT DETERMINATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; NEOPLASM, RESIDUAL; TREATMENT OUTCOME;

EID: 19444382822     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.11.932     Document Type: Editorial

References (12)

1. International Workshop on Chronic Lymphocytic Leukemia: Chronic lymphocytic leukemia: Recommendations for diagnosis, staging, and response criteria. Ann Intern Med 110:236-238, 1989
2. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
3. Montserrat E, Alcala A, Parody R, et al: A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer 56:2369-2375, 1985
4. Catovsky D, Fooks I, Richards S: Prognostic factors in chronic lymphocytic leukaemia: The importance of age, sex, and response to treatment in survival. Br J Haematol 72:141-149, 1989
5. Keating MI, O'Brien S, Kantarjian H, et al: Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81:2878-2884, 1993
6. van Dongen JJM, Langerak AW, Brüggemann M, et al: Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257-2317, 2003
7. Rawstron AC, Kennedy B, Evans PA, et al: Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98:29-35, 2001
8. Moreton P, Kennedy B, Lucas G, et al: Eradication of minimal residual disease in b-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23:2971-2979, 2005
9. Provan D, Bartlett-Pandite L, Zwicky C, et al: Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 88:2228-2235, 1996
10. Bosch F, Ferrer A, López-Guillermo A, et al: Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 119:976-984, 2002
11. Montserrat E: Assessing prognosis in patients with chronic lymphocytic leukemia a quarter of century after Rai and Binet staging systems. Ann Oncol 15:450-451, 2004
12. Rawstron AC, Villamor N, Zehnder JL, et al: International standardized approach to molecular and flow cytometric disease monitoring in CLL. Blood 104:8a, 2004 (abstr)